Merck & Co's Keytruda cancer immunotherapy is set to become the world's top-selling drug by annual revenue in 2023, smashing sales records set by AbbVie's inflammatory disease drug Humi
NICE has said Roche's Tecentriq (atezolizumab) should not get regular NHS funding in first draft guidance as a treatment for metastastic triple negative breast cancer (TNBC), saying that it
NICE has recommended the NHS should fund Novartis’ Luxturna for a rare eye disorder, after the company agreed a discount from the list price of more than £613,000 per patient.
The UK’s GW Pharma has insisted there will be no repeat of the controversy seen with cystic fibrosis drugs after NICE said “no” to regular NHS funding for its Epidyolex for rare forms of ch